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AntiviralHuman APOBEC3G (hA3G), a cytidine deaminase with two cytidine deaminase domains (CDs), has been
identiﬁed as an anti-HIV-1 host factor. Although the two CDs of hA3G have been extensively characterized,
there is still debate on the role of the CDs in the biological function of hA3G. In this work, we constructed three
hA3G mutants CD1-1, CD2-2 and CD2-1, which contain duplicate CD1 domain, duplicate CD2 domain and
position switched CD domain respectively, and investigated the effect of CD domain replacement or switch
upon virion encapsidation, Vif-mediated degradation, deamination and antiviral activity of hA3G. The results
showed that the two CD domains were functionally equivalent in virion encapsidation and the interaction
with HIV-1 Vif of hA3G, whereas CD domain switch or replacement greatly affected the sensitivity to Vif
induced degradation, editing and antiviral activity of hA3G. Although the CD2 domain was shown to possess
the deamination activity, CD2-2 incorporated efﬁciently into HIV-1 was unable to mutate viral cDNA,
suggesting that CD1 also involved in the enzymatic function. Interestingly, CD2-1 retained considerable
deamination activity with a different sequence preference. Taken together, our results suggest that CD domain
may play a structural role in virion encapsidation and Vif-mediated degradation of hA3G, and coordination of
the two CD domains is required for its editing and antiviral activity.chnology, Chinese Academy of
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Lentiviruses, with the exception of equine infectious anemia virus,
all encode a 23 kDa accessory protein Vif (virion infectivity factor)
(Dettenhofer et al., 2000; Fisher et al., 1987; Gabuzda et al., 1992;
Gibbs et al., 1994; Kan et al., 1986; Lee et al., 1986; Madani and Kabat,
1998; Simon et al., 1998; Simon and Malim, 1996; Sodroski et al.,
1986). Vif is an important regulator of viral infection,which is required
for the human immunodeﬁciency virus type 1 (HIV-1) to replicate in
certain “non-permissive” cell types, such as primary T lymphocytes
and H9, but is not required in other “permissive” cell types, such as
SupT1 and Jurkat cells (Fisher et al., 1987; Gabuzda et al., 1992; Strebel
et al., 1987). Non-permissive cells contain a host cellular factor called
human APOBEC3G (apolipoprotein B mRNA-editing enzyme catalytic
polypeptide-like 3G, hereafter referred to as hA3G), which prevents
HIV-1 replication in the absence of Vif (Sheehy et al., 2002). hA3G is
incorporated into HIV-1 virions during virus assembly and inhibits
viral replication in the newly infected cells. Vif is able to bind to hA3G(Mariani et al., 2003) and can reduce both the cellular expression of
hA3G and its incorporation into virions (Kao et al., 2003; Stopak et al.,
2003). Several lines of evidence have demonstrated that Vif induces
the rapid degradation of hA3G by a proteasome-dependent mecha-
nism (Yu et al., 2003).
APOBEC3G belongs to an APOBEC superfamily containing at least 11
members, including activation-induced deaminase (AID), APOBEC1,
APOBEC2, APOBEC3A–H, and APOBEC4 (Conticello et al., 2005; Harris
and Liddament, 2004; OhAinle et al., 2006; Rogozin et al., 2005). Each
APOBEC protein contains one or two copies of cytidine deaminase
domain (CD, a conserved His-X-Glu and Cys-X-X-Cys Zn2+ coordina-
tion motif). Seven APOBEC3 proteins have been identiﬁed as innate
inhibitors of retrovirus replication and retrotransposonmobility (Cullen,
2006). In contrast to hA3A, hA3C and hA3H, which have single catalytic
domain, hA3G contains two tandemCD domains and it is proven to be a
more potent inhibitor of HIV-1 infectivity than other APOBEC3 proteins.
While several reports have shown that the two CD sof hA3G display
quite distinct functional properties—the N-terminal CD1 mediates RNA
binding and virion encapsidation, and the C-terminal CD2 conducts
deaminase catalytic activity (Hache et al., 2005; Iwatani et al., 2006;
Navarro et al., 2005; Newman et al., 2005), there is still a debate on the
role of the CDs in the biological function of hA3G. For instance, the N-
terminal truncations of hA3G, in which the CD1 domain is missing, are
Fig. 1. The incorporation of hA3G and its CD mutants into HIV-1. A. Illustration of the
wild-type and mutated hA3G. The top drawing shows the sequence of two zinc
coordination motif, CD1 and CD2; the lower drawing shows the wild-type and mutant
hA3G, with numbers representing the amino acid positions. B. 293T cells were co-
transfected with plasmids containing vif deﬁcient HIV-1 proviral DNA and plasmids
containing different wild type or mutant hA3G. The plasmids used are listed along the
top of each panel and described under “Experimental procedures”. Western blots of cell
lysates were probed with anti-HA (top panel), anti-β-actin (bottom panel) antibodies.
C. Viruses produced by the 293T cells were puriﬁed and lysed in radioimmune
precipitation assay buffer. The lysate was analyzed by Western blots and was probed
with either anti-HA (upper panel) or anti-CA (lower panel) antibodies. D. 293T cells
were co-transfected with wild type or mutant hA3G expression vector and plasmids
BH10.vif− or ZWt-p6.Vif− proviral DNA. Viruses produced by the cells were puriﬁed,
lysed and analyzed by Western blots. E. The cell lysates were subjected to RNase
treatment, followed by immunoprecipitation with the anti-HA antibody. The
precipitated proteins were analyzed by Western blotting using the anti-Gag antibody.
131X. Li et al. / Virology 414 (2011) 130–136able to be packaged into HIV-1 virions (Cen et al., 2004; Luo et al., 2004;
Zennou et al., 2004), whereas mutations in conserved residues in CD1
prevent virion encapsidation of hA3G (Navarro et al., 2005). An intact
CD2 domain retained deaminase activity in an Escherichia coli reporter
system but failed to mutate viral genome (Chen et al., 2008). To further
characterize the two CDs of hA3G, we have herein constructed three
hA3G mutants: CD1-1 (containing duplicate CD1 domain), CD2-2
(containing duplicate CD2 domain) and CD2-1 (containing position
switched CD1 and CD2 domain) and investigated the effect of CD
domain switch or replacement upon viral incorporation, Vif-mediated
degradation and antiviral function of hA3G.
Result
The incorporation of CD mutants into HIV-1
The CD1 and CD2 domains share high homology (Fig. 1A), and they
are predicted to adopt similar structures (Jarmuz et al., 2002). Using
fusion PCR, we have constructed three hA3G mutants containing a C-
terminal HA tag (Fig. 1A): CD1-1, with the C-terminal CD domain (CD2)
replaced with the identical N-terminal one (CD1); CD2-2, with the CD1
domain replaced with the identical CD2 domain; and CD2-1, with the
positionof CD1andCD2domain switched(Fig. 1A).Weﬁrst checked the
viral encapsidation of the threemutants. 293T cells were co-transfected
with plasmids containing vif deﬁcient HIV-1 proviral DNA and plasmids
containing different wild type or mutant hA3G. The cell lysates of
transfected cells were analyzed by Western blots (Fig. 1B), using anti-
HA (top panel) and anti-β-actin (bottom panel) antibodies as probes.
Both wild type andmutant hA3Gwere expressed at similar levels in the
cytoplasm. The viruses produced from these cells were puriﬁed and
were also analyzed by Western blotting (Fig. 1C), using anti-HA (top
panel) and anti-CAp24 (bottom panel). The result shows that all hA3G
mutants were incorporated into the virion at levels similar to wild type
hA3G. It indicates that the replacement or switch of CDs has no effect on
hA3G viral incorporation.
It is known that HIV-1 nucleocapsid (NC) domain within Gag is
required for hA3G packaging likely through an RNA-mediated
mechanism (Svarovskaia et al., 2004). To determine whether the
mutated forms of hA3G were incorporated into HIV through the same
mechanism as wild type hA3G does, we checked whether the
packaging of hA3G mutants into virions requires the presence of NC
domain and whether their interactions with HIV-1 Gag is RNA
dependent. ZWt-p6.vif− encodes a Vif deﬁcient full-length HIV-1
genome, in which the nucleocapsid sequence has been replaced with
a yeast leucine zipper domain (Accola et al., 2000). It has been shown
that the mutated HIV-1 Gag is able to assemble into virus like particle
but fail to incorporate hA3G (Accola et al., 2000). Fig. 1D showed that,
in contrast to BH10.Vif-, ZWt-p6.Vif− almost lost its ability to
incorporate hA3G or its mutants. We next transfected 293T cells
with the plasmid containing hGag and APOBEC3G and treated the cell
lysates with RNase prior to immunoprecipitation with the anti-HA
antibody. The precipitated proteins were analyzed by Western
blotting using the anti-p24 antibody. The result shows that the
RNase treatment diminished the co-immunoprecipitation of hA3G or
its variants with Gag (Fig. 1E). These results indicate that virion
encapsidation of the three mutants required the NC domain and that
their interactions with HIV-1 Gag are sensitive to RNase, suggesting
that themutated forms of hA3G are incorporated into HIV through the
same mechanism as wild type hA3G does.
The interaction between HIV-1 Vif and hA3G CD mutants
The current consensus view is that HIV-1 Vif protein interacts with
hA3G as a part of a Vif–Cul5–SCF complex, thus resulting in
polyubiquitination and proteosomal degradation of hA3G (Yu et al.,
2003). Previous studies have shown that the Vif/hA3G interactioninvolves the N-terminal region of the linker sequence within hA3G
(Conticello et al., 2003; Marin et al., 2003; Zhang et al., 2008), while
whether themotifs located outside of the region, especially the two zinc
coordination motifs, affect Vif-mediated degradation is not known.
132 X. Li et al. / Virology 414 (2011) 130–136To address the question, 293T cells were co-transfected with
plasmids coding HIV-1 vif and plasmids containing either wild type or
mutant hA3G. Western blot of cell lysates showed that the expression
of wild type and variant CD1-1 was greatly reduced in the presence of
Vif, while both variant CD2-2 and CD2-1 were relatively resistant to
Vif (Fig. 2A). Since the hA3G/Vif interaction is a prerequisite for the
degradation of hA3G, we next investigated if the resistance of CD2-2
and CD2-1 to Vif resulted from their inabilities to binding with Vif.
293T cells were transfected as described above and then treated with
MG132, a proteasome inhibitor, at 24 h post-transfection. The lysates
of transfected cells were analyzed by Western blots (Fig. 2B). The
abilities of the different hA3G variants to bind to Vif were assessed by
co-immunoprecipitation with mouse anti-HA and detected by rabbit
anti-vif as shown in Fig. 2C. We found a similar amount of Vif present
in the immunoprecipitate of the hA3G mutant, while CD2-2 and CD2-
1 showed increasing cellular content, which may reﬂect weaker
interaction of Vif with CD2-2 and CD2-1 than wild type hA3G. ThisFig. 2. The interaction between HIV-1 Vif and hA3G CD mutants. 293T cells were co-
transfected with wild type or CD mutant hA3G expression vectors and plasmid coding
for HIV-1 Vif protein. Interaction between Vif and hA3G CD mutants was measured by
co-immunoprecipitating these molecules from cell lysate with anti-HA. A. The cell
lysates were probed with anti-HA (top panel), anti-Vif (bottom panel) antibodies. B. In
the presence of MG132, Western blots of cell lysate were probed with anti-HA (top
panel), anti-Vif (bottom panel) antibodies. C. The cell lysates were incubated with the
mouse anti-HA antibody and then detected by rabbit anti-HA (upper panel) and anti-
Vif (lower panel) antibodies.indicates that domain replacement or switch of CDs has no signiﬁcant
effect in hA3G/Vif interaction, whereas replacing CD1 with CD2
impairs the sensitivity of hA3G to Vif.
Cytidine deamination activity of CD mutants
Several groups previously reported that the CD2 of hA3G is
responsible for its deamination activity and replacement of the
conserved cystine, histidine or glutamic amino acid in CD2 domain did
not affect its viral incorporation but greatly impaired its catalytic
activity (Hache et al., 2005; Iwatani et al., 2006; Navarro et al., 2005;
Newman et al., 2005). To determine whether the CD domain switch or
replacement affect the editing activity of hA3G, SupT1 cells were
infected by the virions containing wild type or CD mutated hA3G, and
then the proviral DNA was extracted from these cells 48 h post-
infection. PCR products representing the BH10 DNA sequence 492–
764 (containing the R, U5 and part of gag region) were sequenced and
examined for mutations. Compared to hA3G which caused 1.76 G to A
mutations per 100 bases in viral cDNA, the variant CD2-1 retains
considerable deamination activitywhich caused 0.51 G to Amutations
per 100 base bases (Fig. 3A), whereas the variants CD1-1 and CD2-2
completely lost their deamination activity.
Interestingly, we found that the switch of the CD domain affected
nucleotide sequence preference pattern of the deaminase. The
preferred sequence context for wild type hA3G is GG (where the
edited is underlined) which can be mutated at frequencies N91%,
while the mutation frequency of other sequence context which differ
in +1 position such as GA, GT and GC is below 5%. However, in CD2-1
induced G to A mutations, although the sequence context of GG is still
the most preferred context for CD2-1(N84%), the sequence context of
GT is signiﬁcantly increased to over 14% (Fig. 3B). We next
investigated if the mutations affect sequence preference in −1
position of the edited guanosine. As shown in Fig. 3C, the result
reveals that the sequence preference of either hA3G or CD2-1 did not
correlated with frequency of the four kinds of GG context in HIV-1
genome (AGG (29.6%), TGG (25.9%), CGG (13.0%) and GGG (31.5%)).
The TGG is preferred by wild type hA3G, which covers 56% of GG
context mutations while other three kinds of GG context only cover
8.8%–23.5%. However, in CD2-1 variant induced mutations, both TGG
and GGG are preferred, which covers approximately 45.5% and 49.3%
respectively (Fig. 3C). These data demonstrated that switch of CD
domain of hA3G greatly affected its sequence preference in −1
position of the edited guanosine.
Anti-viral activity of zinc coordination motif mutants
Wild type hA3G and CD mutants were next examined for their
inhibitory effect on vif-deﬁcient HIV-1 in a single-round infection
assay (Fig. 4A). Compared to the wild-type hA3G, the antiviral
activities of the three CDmutants were signiﬁcantly decreased: CD1-1
and CD2-2 retained about 27.3% and 10.0% of inhibition activity
respectively, whereas CD2-1 completely lost its anti-HIV activity.
Previous studies have shown that, in addition to mutate viral cDNA,
hA3G inhibits HIV-1 replication through non-deaminating mechanism,
e.g. inhibition of viralDNAsynthesis and integration (Bishop et al., 2008;
Li et al., 2007; Luo et al., 2007). Therefore, we next investigatedwhether
anti-viral activity of CD1-1 and CD2-2, two deaminating activity
deﬁcient hA3G mutants, is derived from the inhibition of viral DNA
synthesis. Real-time PCR quantitation of newly synthesized HIV-1 DNA
shows that, in the presence of CD1-1 and CD2-2, the late DNA synthesis
is decreased 71.0% and 54.3% respectively, whereas CD2-1 had little
effect to viral DNA synthesis (Fig. 4B). These data suggested that the
antiviral activity of CD1-1 and CD2-2 may result from the inhibition of
viral DNA synthesis via a non-deaminating mechanism described
previously (Bishop et al., 2008; Li et al., 2007; Luo et al., 2007).
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Fig. 3. Deamination activity of wild type and mutant hA3G. 293T cells were co-
transfected with plasmids containing vif deﬁcient HIV-1 proviral DNA and different
wild type or mutant hA3G plasmids. DNA was extracted from these cells 16 h later, and
PCR products representing the BH10 DNA sequence 469–699 (containing sequences
starting form R region and ending in gag region) were sequenced and examined for
mutations. A. The frequency of G to A mutation in the presence of wild type or mutant
hA3G in Vif deﬁcient proviral HIV-1. B. Comparison of the preferred sequence in +1
position relative to the substrate G. C. Comparison of the preferred sequence in −1
position relative to the substrate G.
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Fig. 4. Antiviral function of hA3Gmutant proteins. A. Single cycle HIV-1 infectivity assay
on TZM-bl reporter cell lines. 293T cells were co-transfected with plasmids containing
vif deﬁcient HIV-1 proviral DNA and different wild type or mutant hA3G plasmids.
Culture supernatants were collected 48 h post-infection and quantiﬁed by measuring
amounts of p24. The levels of infectious viruses were determined by infecting the TZM-
bl indicator cells. B. qPCR quantiﬁcation of newly synthesized late viral DNA. DNA was
extracted from SupT1 cells at 16 h post-infection with vif deﬁcient HIV-1 containing
wild type or mutant hA3G. Late (U5-gag) viral cDNA production was monitored by
qPCR, as described in Experimental procedures.
133X. Li et al. / Virology 414 (2011) 130–136Discussion
APOBEC3 genes are speciﬁc to mammals and are organized in a
tandem array between two vertebrate-conserved ﬂanking genes,
CBX6 and CBX7 (LaRue et al., 2008). Seven human APOBEC3 genes are
located chromosome 22 at q13.2 in a head-to-tail manner. One study
based on phylogenetic analyses suggests that the ancestral members
of APOBEC3 have only one CD which might be derived from AID orAPOBEC2 (Conticello et al., 2005) and then formed an APOBEC3
subfamily through gene duplication under signiﬁcant selective
pressure which might be related to prevention human endogenous
retroviruses and retrotransposons from causing genomic instability
(Sawyer et al., 2004; Wedekind et al., 2003; Zhang and Webb, 2004).
While four APOBEC3 proteins (hA3B, hA3DE, hA3F, and hA3G) have
two CD domains, hA3A, hA3C, and hA3H only have one deaminase
motif. Whether duplication of the CD domain is related to its
inhibitory activity has remained unclear. Indeed, some reports
indicated that single domain APOBEC3 proteins show a very weak
anti-viral activity of HIV (Yu et al., 2004). However, single domain
APOBEC3 protein hA3A potently inhibits parvovirus adeno-associated
virus (AAV) as well as endogenous retroelements (Chen et al., 2006),
and recent ﬁndings also showed that single domain A3H is a potent
inhibitor of HIV (Dang et al., 2008; Harari et al., 2009; Zhen et al.,
2010).
134 X. Li et al. / Virology 414 (2011) 130–136The CD1, but not CD2, of hA3G has been reported to mediate RNA
binding and virion encapsidation (Iwatani et al., 2006; Navarro et al.,
2005; Newman et al., 2005), and site mutation or deletion of
conserved amino acids in CD1 prevents hA3G encapsidation (Friew
et al., 2009; Navarro et al., 2005). However, our work showed here
that the hA3G variants CD2-2 was able to be packaged efﬁciently into
HIV-1 through a mechanism that wild-type hA3G dose. These data
suggest that the CD1 domain is not required for viral incorporation of
hA3G, or its role if any is not in a sequence speciﬁc manner. One
explanation for this controversy is that the CD1 may be involved in
viral incorporation of hA3G indirectly, e.g. maintain a proper
conformation that is required for the hA3G/Gag interaction. It is
possible that, in contrast to mutating conserved amino acids in CD1,
switching structural homology CDs does not impact on the integral
conﬁguration of the protein, thereby having no effect upon its viral
incorporation. In agreementwith this hypothesis, several key residues
of hA3G essential for its viral incorporation have been mapped in a
linker region between the two CDs (Khan et al., 2009; Zhang et al.,
2007), and several group also reported that various motifs outside of
CD1 of APOBEC3 proteins have been reported to mediate RNA binding
and virion targeting (Huthoff et al., 2009; Wang et al., 2007, 2008;
Zhang et al., 2010). In addition, our previous study demonstrates that
the linker region is required for hA3G viral incorporation, and removal
of the N-terminal 104 amino acids (including the CD1 domain) does
not affect the ability of hA3G to be packaged into Gag VLPs (Cen et al.,
2004).
One common feature of APOBEC family members is that they all
possess single strand DNA/RNA deamination activity. Several groups
previously reported that C-terminal CD2 domain of hA3G exhibits its
deaminase catalytic activity (Hache et al., 2005; Iwatani et al., 2006;
Navarro et al., 2005; Newman et al., 2005); it is therefore expected
that the hA3G variant CD1-1 did not show any deamination activity
(Fig. 4). Surprisingly, the h3G variant CD2-2 which contains two
catalytic CD2 domains was also unable to mutate HIV-1 cDNA, even
though its viral content was the same as wild type hA3G (Fig. 1). Our
previous work has shown that hA3G C-terminal fragment (104–384)
missing CD1 is unable to create G–A deamination mutations on viral
cDNA (Guo et al., 2006). These results imply that, in addition to CD2,
CD1 is also required for editing HIV-1 cDNA. In agreement with this,
we did ﬁnd that, among the three hA3G variants tested, CD2-1 is the
sole mutant that possesses considerable deamination activity and
contains both the CD domains.
Furthermore, our data indicate that CD domain switch affected the
local nucleotide sequence preferences of hA3G. Although GG context
remains themost preferred hotmutation spot for CD2-1, themutation
created in GT sequence context increased signiﬁcantly compared with
wild type hA3G. The data also show that, in contrast to hA3G which
prefers T in −1 positions relative to the substrate G, and 56% G–A
mutations are shown in TGG context, CD2-1 variant prefers both GGG
(49%) and TGG (46%). It has been reported that the sequence
preference is determined by the CD2 domain of APOBEC proteins
(Hache et al., 2005); our result demonstrates here that factors other
than catalytic site itself of hA3G are also involved. Indeed, previous
studies have shown subtle shifts in speciﬁcity of RNA editing when
site-directed mutations at positions outside of CD2 in APOBEC3
proteins, e.g., D311Y mutation of hA3F (Kohli et al., 2009), D316R/
D317R double mutant of hA3G (Rausch et al., 2009). A recent work
has identiﬁed a recognition loop of 9–11 amino acids located
downstream of catalytic site of APOBEC proteins, which contributes
signiﬁcantly to the distinct sequence motifs of individual family
members (Kohli et al., 2009). It is possible that this recognition loop,
which is grafted from the downstream of CD2 into the corresponding
sequence of CD1, causes the change in mutational signature of CD2-1.
Although CD2-1 retains 30% of deamination activity of wild type
hA3G, this variant completely lost its inhibition activity. On the
contrary, the variant CD1-1 that has no editing activity retains about27.3% anti-HIV-1 activity. This result suggests that although the
deaminase activity of hA3G plays an important role in the inhibition of
HIV-1 replication, the editing-independent antiviral mechanism is
also required for the maximal potency of the innate immunity against
HIV-1 infection.
Experimental procedures
Plasmid construction
BH10 is a simian virus 40-based vector that contains full-length
wild-type HIV-1 proviral DNA. The construction of BH10.vif−, as well
as wild-type hA3G has been previously described (Cen et al., 2004).
ZWt-p6.vif− encodes a Vif-deﬁcient full-length HIV-1 genome, in
which the nucleocapsid sequence has been replaced with a yeast
leucine zipper domain (Accola et al., 2000). The hGag plasmid, which
encodes the HIV-1 Gag sequence, produces mRNAwhose codons have
been optimized for mammalian codon usage was a kind gift from G.
Nabel, National Institutes of Health (Huang et al., 2001). The Vif
expression plasmid pcDNA-HVif was kindly provided by Klaus Strebel,
National Institutes of Health (Nguyen et al., 2004). The domain
replaced and switched hA3G cDNAs were generated by overlapping
extension PCR, using wild type hA3G expression plasmids as template
(Cen et al., 2004). Each cDNA fragments were ampliﬁed separately, by
using a primer speciﬁc for the overlap region; for replacement of CD2
with CD1, the following intermediate primers were used: (A1) 5′ TCT
CAT CTC TGG GTG GCG GCC TTC AAG GAA 3′; (A2) 5′ TTC CTT GAA
GGC CGC CAC CCA GAG ATG AGA 3′; (A3) 5′ AGC CAT TTC CTG GGC
ACA CTT TGT GCA GGG 3′; (A4) 5′ CCC TGC ACA AAG TGT GCC CAG
GAA ATG GCT 3′; for replacement of CD1 with CD2, the following
intermediate primers were used: (B1) 5′ ACA GCT CTG CAT GGT ACT
TAA GTT CG GA 3′; (B2) 5′ TCC GAA CTT AAG TAC CAT GCA GAG CTG T
3′; (B3) 5′ GCC ATA TCC CTT GTA CAG CTG AAG CAG G 3′; (B4) 5′ CCT
GCT TTC AGC TGT ACA AGG GAT ATG GC 3′; the N-terminal and C-
terminal primer were same as wild type hA3G: 5′-TAA GCG GAA TTC
ATG AAG CCT CAC TTC AGA (forward primer) and 5′-TAG AAG CTC
GAG TCA AGC GTA ATC TGG AAC (reverse primer). The ampliﬁed PCR
products were digested with EcoRI and XhoI, whose sites were placed
in each of the PCR primers. These fragments were cloned into the
EcoRI and XhoI sites of the pcDNA3.1V5/His vector.
Cells, transfections, and viruses puriﬁcation
HEK-293T cells and TZM-bl cells were grown in complete
Dulbecco's modiﬁed Eagle's medium plus 10% fetal calf serum, 100
units of penicillin, and 100 μg of streptomycin/ml. HEK-293T cells
were transfected using Lipofectamine 2000 (Invitrogen) according to
themanufacturer's instructions. In Vif/hA3G interaction assay (Vif and
hA3G/mutants plasmid co-transfected 293 cells with a ratio of 1:1),
MG132 was added to the transected cells 24 h post-transfection (ﬁnal
concentration of 5 μM). Cells were collected 48 h post-transfection for
protein or immunoprecipitation assay. For the production of viruses
or Gag VLP (293 cells were co-transfected hGag and hA3G/mutants
plasmid with a ratio of 1: 1), supernatant was collected 48 h post-
transfection. Viruses were pelleted from culture medium by centri-
fugation in a Beckman Ti-45 rotor at 35,000 rpm for 1 h. The viral
pellets were then puriﬁed by centrifugation in a Beckman SW 41 rotor
at 26,500 rpm for 1 h through 15% sucrose onto a 65% sucrose cushion.
The band of puriﬁed virus was removed and pelleted in 1× TNE
(20 mM Tris, pH 7.8, 100 mM NaCl, 1 mM EDTA) in a Beckman SW 41
rotor at 40,000 rpm for 1 h.
Protein analysis
Cellular and viral proteins were extracted with radioimmune
precipitation assay buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1%
135X. Li et al. / Virology 414 (2011) 130–136sodium deoxycholate, 0.1% SDS, 1% Nonidet P-40, 2 mg/ml aprotinin,
2 mg/ml leupeptin, 1 mg/ml pepstatin A, 100 mg/ml phenylmethyl-
sulfonyl ﬂuoride). The cell and viral lysates were analyzed by SDS–
PAGE (10% acrylamide), followed by blotting onto nitrocellulose
membranes (GE HealthCare). Western blots were probed with
monoclonal antibodies that are speciﬁcally reactive with HIV-1 capsid
(Zepto Metrocs Inc.), hA3G (NIH AIDS Research and Reference
Reagent Program), hemagglutinin (HA, Santa Cruz Biotechnology,
Inc.), and β-actin (Sigma), or with Vif-speciﬁc polyclonal antiserum
2221 (NIH AIDS Research and Reference Reagent Program). Detection
of proteins was performed by enhanced chemiluminescence (Perki-
nElmer Life Sciences), using secondary anti-mouse (for hA3G, capsid,
HA, and β-actin) and anti-rabbit (for Vif) antibodies, both obtained
from GE Health Care. Bands in Western blots were quantitated using
the Image J 1.35s automated digitizing system (National Institutes of
Health).
Immunoprecipitation assay
293T cells from 100-mm plates were collected 48 h post-
transfection and lysed in 500 μl of CytoBuster Protein Extraction
Reagent (novagen). Insoluble material was pelleted at 1800g for
30 min. The supernatant was used as the source of immunoprecipi-
tated complexes. Equal amounts of protein were incubated with 5 μl
of speciﬁc antibody for 16 h at 4 °C. In Vif/hA3G mutants complexes
assay, speciﬁc anti-HA mouse antibody (Santa Cruz Biotechnology)
was used and for Gag/hA3G complexes assay, speciﬁc anti-HA rabbit
antibody was used (Santa Cruz Biotechnology), followed by the
addition of protein A-Sepharose (AmershamBiosciences) for 2 h. The
immunoprecipitate was then washed three times with TNT buffer
and twicewith phosphate-buffered saline. After theﬁnal supernatant
was removed, 30 μl of 2× sample buffer (120 mM Tris–HCl, pH 6.8,
20% glycerol, 4% SDS, 2% β-mercaptoethanol, and 0.02% bromphenol
blue) was added, and the precipitate was then boiled for 5 min to
release the precipitated proteins. After microcentrifugation, the
resulting supernatant was analyzed using Western blots. In the
RNase treatment assay, the cell lysates were pretreated with 100 μg
RNase before the immunoprecipitation, as described previously
(Khorchid et al., 2002).
Sequencing of viral genomic DNA
The sequencing of viral genomic DNA was performed as follows.
Viral supernatants from transfected 293 cells were ﬁltered through
0.45-μm ﬁlters and treated with DNase at 100 IU/ml for 1 h at 37 °C to
prevent proviral DNA carryover. A total of 10 ng viral p24 was used to
infect 2×105 SupT1 cells in 24 well plate using spin infection; add
polybrene (Sigma H9268) to a ﬁnal concentration of 4 μg/ml; spin at
1000g (Beckman centrifuge GPH, Rotor 3.7, 2500 rpm) for 120 min at
room temperature. After spinning, the infected cells were washed
twice with phosphate-buffered saline and plated into six-well plates.
Complete RPMI 1640 medium prewarmed to 37 °C was added to the
infection mixture. Cultured cells were collected 24 h post-infection,
and DNA was extracted using a DNeasy Blood and tissue kit (QIAGEN
Inc.). PCR was performed with Platinum Taq polymerase (Invitrogen
Life Technologies). The primers were as follows: forward (469 to 492),
5′-TTAGACCAGATCTGAGCCTGGGAG-3′; reverse (679 to 699), 5′-
GAGTCCTGCGTCGAGA GAGCT-3′. The PCR products were cloned
into pCR4-TOPO vector (Invitrogen Life Technologies), and individual
clones were sequenced.
Single cycle HIV-1 infectivity assay on TZM-bl reporter cell lines
293T cells were co-transfected with plasmids containing vif
deﬁcient HIV-1 proviral DNA and different wild type or mutant
hA3G plasmids. Culture supernatants were collected 48 h post-infection and quantiﬁed by measuring the amounts of p24 using
HIV-1 p24 ELISA kit (Xpressbio, Thurmont, MD, USA) following the
manufacturer's instructions. TZM-bl cells (4×104) were infected with
equal amounts (20 ng p24 antigen) of Vif deﬁcient HIV-1 containing
wild-type or mutant hA3G. Forty-eight hours post-infection, cells
were harvested in 200 μl 1× Luciferase Cell Culture Lysis Reagent
(Promega) and assayed for luciferase activity with the luciferase assay
kit (Promega).
Real-time PCR quantitation of newly synthesized HIV-1 DNA
Equal amounts of DNase-treated virions (100 ng p24)were used to
infect 1×106 SupT1 cells using spin infection as previously described.
Cultured cells were collected 16 h post-infection, and DNA was
extracted using a DNeasy Blood and tissue kit (QIAGEN Inc.). Using
equal amounts of cellular genomic DNA (determined spectrophoto-
metrically at an optical density of 260 nm), late (U5-gag) minus-
strand reverse transcripts were quantitated by the Light Cycler
Instrument (Roche Diagnostics GmbH) using the following primers:
late RT forward (560 to 578), 5′-TGTGTGCCCGTCTGTTGTGTGA-3′; late
RT reverse (679 to 699), 5′-GAGTCCTGCGTCG AGAGAGCT-3′.
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